Adverum Biotechnologies, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 154.54 million compared to USD 145.54 million a year ago. Basic loss per share from continuing operations was USD 15.6 compared to USD 14.8 a year ago.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
7.6 USD | -2.94% | -5.47% | +0.96% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.96% | 158M | |
+12.30% | 118B | |
+12.15% | 106B | |
-8.14% | 23.4B | |
-0.29% | 21.78B | |
-9.28% | 18.09B | |
-41.70% | 16.72B | |
-15.33% | 15.97B | |
+5.80% | 14.03B | |
+28.03% | 11.67B |
- Stock Market
- Equities
- ADVM Stock
- News Adverum Biotechnologies, Inc.
- Adverum Biotechnologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022